Seeking Alpha

Seeking Alpha Portfolio App for iPad

4,237 people get QCOR articles and Market Currents by email alert.

Get email alerts on QCOR »

QCOR

Questcor Pharmaceuticals, Inc.

5/23/2013, 7:16 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 8:03 PM Questcor Pharmaceuticals (QCOR +13.07%) sits idle in the post session today as the company gets its presentation at the BofA/Merrill health-care conference underway. While not likely to provide any sweeping new information, the presentation will paint a clearer picture of what lies ahead for Acthar gel in the realm of an alternative treatment for certain rheumatology-related conditions. According to Janney Montgomery spelling out the numbers of patients needing alternative treatment could what drove some shorts to cover today. Short interest on the stock stands at about 45%. Comment! [Healthcare, On the Move]
Monday, May 13, 3:56 PM The 25 most heavily shorted stocks (as a percent of float) in the S&P 1500 as of the end of April are up 6.75% in May, trouncing the S&P's 2.33% gain, according to Bespoke - and this doesn't include Tesla, up 57% with 40% of its float shorted, but not a S&P 1500 member. The top 5 heavily shorted: BTH, QCOR, CSTR, BRLI, SPPI. The rest in another post. 4 Comments
Tuesday, April 30, 4:30 PM More on Questcor Pharmaceuticals (QCOR): Q1 misses badly on all counts, despite a 41% jump in Y/Y net sales. The company says that the quarter was negatively impacted by several transitional events, including: distribution channel disruptions due to the Medicaid rebate change, the timing of Acthar orders that were received and filled and the introduction of a new reimbursement support center. Additionally, the company experienced a reduction in the number of Acthar prescriptions to treat MS exacerbations. Shares -8.3% AH. 4 Comments [Healthcare, Earnings, On the Move]
Tuesday, April 30, 4:18 PM Questcor Pharmaceuticals (QCOR): Q1 EPS of $0.76 misses by $0.20. Revenue of $135M (+41% Y/Y) misses by $22M. (PR). Shares -9.3% AH. 4 Comments [Healthcare, On the Move, Breaking News]
Tuesday, February 26, 6:11 PM More on Questcor Pharmaceuticals (QCOR): Q4 beats on all counts as total revenue jumped 113% Y/Y, primarily due to expanded Acthar prescriptions in the treatment of nephrotic syndrome as well as the treatment of MS relapses and infantile spasms. Net sales also benefited from the initiation of commercial activities focused on the use of Acthar in the treatment of rheumatology-related conditions. Despite the overall better numbers, the shares are -6.6% AH. 11 Comments [Healthcare, Earnings, On the Move]
Tuesday, February 26, 5:51 PM After-hours top gainers, as of 5:15 p.m.: GWRE +9%. BGFV +8%. UVXY +5%. ZAGG +5%. TVIX +4%.
After-hours top losers: FSLR -10%. AH -10%. MERU -9%. QCOR -6%. SPWR -5%. 3 Comments [On the Move]
Tuesday, February 26, 4:15 PM Questcor Pharmaceuticals (QCOR): Q4 EPS of $1.09 beats by $12. Revenue of $160.5M beats by $18M. (PR). Shares -2% AH. 9 Comments [Healthcare, Breaking News, Earnings]
Tuesday, February 26, 12:10 AM Notable earnings after Tuesday’s close: AVGO, AWK, DGI, DWA, EIX, FSLR, GA, GPOR, GWRE, HRZN, JAZZ, MAKO, MIDD, NUVA, ORA, PCLN, QCOR, RENN, REXX, RRC, SPN, STEC, TIVO, VNO, VRSK, ZAGG Comment! [Earnings]
Monday, February 25, 5:35 PM Notable earnings after Tuesday’s close: AVGO, AWK, DGI, DWA, EIX, FSLR, GA, GPOR, GWRE, HRZN, JAZZ, MAKO, MIDD, NUVA, ORA, PCLN, QCOR, RENN, REXX, RRC, SPN, STEC, TIVO, VNO, VRSK, ZAGG Comment! [Earnings]
Wednesday, January 2, 6:41 PM Questcor Pharmaceuticals (QCOR) acquires Canadian biotech firm BioVectra for C$50M. BioVectra is a contract manufacturing services provider to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients, chemical intermediates, and bioprocessing reagents. The acquisition is part of a larger strategy by QCOR to lock down a key ingredient maker for its only drug, Acthar, which isn't patent-protected, and will help to protect the drug's manufacturing process trade secrets. 6 Comments [Healthcare, M&A, Global & FX]
Wednesday, January 2, 3:27 PM Shares of Questcor (QCOR -2.6%) are on the move again after UnitedHealthcare (UNH -0.1%) announces in a network bulletin that, effective April 1, 2013, the insurer will require physicians to submit for prior authorization and approval of Acthar for its plan members. 6 Comments [Healthcare, On the Move]
Sunday, December 30, 2012, 11:35 AM At $28K a vial, Questcor's (QCOR) Acthar has propelled shares to huge gains. QCOR bought the drug for $100K in 2001, planning to produce it only to treat infantile spasms. But thanks to aggressive marketing, it's now being prescribed for MS, arthritis, and kidney disease. Aetna's (AET) decision to limit off-label treatments has hit shares, but it's not clear any viable alternatives are on the horizon. (NYT) 32 Comments
Thursday, December 27, 2012, 12:23 PM Questcor (QCOR -6%) gets hit today after Blue Cross/Blue Shield of Michigan denies coverage of it's Acthar Gel for steroid-responsive conditions, saying the clinical need has not been demonstrated. Coverage will continue to be provided however, for treatment of infantile spasms, which is one of its FDA approved indications. 17 Comments [Healthcare, On the Move]
Thursday, December 6, 2012, 5:57 PM After-hours top gainers, as of 5:15 p.m.: ENPH +6%. GEO +6%. FSGI +4%. BAGL +3%. MBTF +3%.
After-hours top losers: AMRN -20%. MBLX -7%. QRE -5%. QCOR -3%. KONG -3%. 1 Comment [On the Move]
Friday, November 30, 2012, 12:30 PM More on Questcor (QCOR -6.4%): Aetna's (AET +0.3%) latest bulletin shows no change from its position first taken in September on Acthar. The insurer is still limiting reimbursement of the drug only for the treatment of infantile spasms. AET asserts that the drug's other approved uses are medically unnecessary or unproven. 2 Comments [Healthcare, On the Move]
Friday, November 30, 2012, 9:52 AM Questcor Pharmaceuticals (QCOR -6.1%) after Mizuho starts the stock off with a Neutral rating and $28 price target. There's also word Aetna is fixing to slash more coverage of Questcor's Acthar. 6 Comments [Healthcare, On the Move]